Seizert Capital Partners LLC Has $61.62 Million Stake in United Therapeutics Corporation $UTHR

Seizert Capital Partners LLC lifted its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 17.1% in the third quarter, HoldingsChannel.com reports. The fund owned 146,991 shares of the biotechnology company’s stock after acquiring an additional 21,450 shares during the period. United Therapeutics makes up 2.7% of Seizert Capital Partners LLC’s investment portfolio, making the stock its 8th largest position. Seizert Capital Partners LLC’s holdings in United Therapeutics were worth $61,620,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in UTHR. AQR Capital Management LLC boosted its holdings in shares of United Therapeutics by 40.1% in the second quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock worth $362,876,000 after acquiring an additional 364,713 shares during the period. Invesco Ltd. increased its holdings in shares of United Therapeutics by 90.2% in the second quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock worth $254,219,000 after purchasing an additional 419,588 shares during the period. Assetmark Inc. raised its position in shares of United Therapeutics by 38.1% in the second quarter. Assetmark Inc. now owns 715,834 shares of the biotechnology company’s stock worth $205,695,000 after buying an additional 197,384 shares in the last quarter. Norges Bank purchased a new position in United Therapeutics during the second quarter worth about $136,453,000. Finally, Amundi increased its stake in United Therapeutics by 3.6% in the 2nd quarter. Amundi now owns 362,826 shares of the biotechnology company’s stock worth $107,113,000 after acquiring an additional 12,633 shares during the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on UTHR shares. Royal Bank Of Canada raised their price objective on United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a report on Thursday, October 30th. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a research report on Monday, December 29th. Wells Fargo & Company boosted their price target on United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a report on Thursday, October 30th. HC Wainwright upped their price objective on shares of United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. Finally, UBS Group boosted their price target on shares of United Therapeutics from $600.00 to $645.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Eight analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and an average target price of $509.50.

Insider Buying and Selling

In other news, Director Christopher Causey sold 1,000 shares of the business’s stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $510.00, for a total transaction of $510,000.00. Following the completion of the sale, the director directly owned 4,190 shares of the company’s stock, valued at approximately $2,136,900. The trade was a 19.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Paul A. Mahon sold 8,300 shares of the stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $469.89, for a total transaction of $3,900,087.00. Following the sale, the executive vice president directly owned 36,781 shares of the company’s stock, valued at approximately $17,283,024.09. The trade was a 18.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 571,314 shares of company stock valued at $269,609,063 in the last three months. Corporate insiders own 10.30% of the company’s stock.

United Therapeutics Stock Down 3.0%

Shares of United Therapeutics stock opened at $457.99 on Tuesday. The company has a market cap of $19.72 billion, a price-to-earnings ratio of 17.35, a price-to-earnings-growth ratio of 2.42 and a beta of 0.84. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $519.99. The company’s 50 day moving average is $487.07 and its 200 day moving average is $410.84.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, beating analysts’ consensus estimates of $6.89 by $0.27. The business had revenue of $799.50 million for the quarter, compared to analysts’ expectations of $812.87 million. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The business’s quarterly revenue was up 6.8% on a year-over-year basis. During the same period last year, the firm earned $6.39 earnings per share. Sell-side analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.